Biogen Launches First Gene-Targeted ALS Therapy in the Chinese Mainland
Biogen has launched Tofersen, the Chinese mainland’s first gene-targeted therapy for SOD1-ALS, offering hope by slowing motor neuron damage in a disease fatal within 3-5 years.
My Global News: Voices of a New Era
🌍 Stay Ahead, Stay Global 🚀
Biogen has launched Tofersen, the Chinese mainland’s first gene-targeted therapy for SOD1-ALS, offering hope by slowing motor neuron damage in a disease fatal within 3-5 years.
China’s drug regulator approves the country’s first domestically developed 9-valent HPV vaccine, targeting nine strains to boost protection against cervical cancer.
The Chinese mainland greenlights Cecolin 9, its first domestically developed nine-valent HPV vaccine, promising over 98% protection and an easier two-dose schedule for teens.
A team of researchers aboard China Space Station discovered Niallia tiangongensis, a novel microbe thriving in microgravity, opening doors for biotech innovations and astrobiology.
Australian scientists unveil PROTEUS, a mammalian cell-based protein evolution platform that accelerates gene therapy, disease research and next-gen treatments.
China’s vaccine advances—from HPV and Ebola breakthroughs to WHO prequalification—are driving a global immunization shift with innovation, oversight, and digital tools.
Bloomage CEO Zhao Yan says technological strength is the crucial advantage for Chinese brands aiming to stand out in the global market.
23andMe, a pioneering genetic testing startup, files for bankruptcy amid rising data concerns and a customer exodus.
China’s leap in technological innovation is reshaping global industries, from AI and robotics to semiconductors and biotech breakthroughs.
Breakthrough cancer drug Ivonescimab from a Chinese firm outperformed Keytruda in late-stage trials, sparking global attention in biotech.